ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2815

A Comparison of Th17 Gene Expression in Psoriatic Arthritis Synovial Fluid and Peripheral Blood

Fatima Abji1, Remy Pollock2, Kun Liang3, Vinod Chandran4 and Dafna Gladman4, 1Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 4Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Gene Expression, psoriatic arthritis and synovial cells, synovial fluid, T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:
Psoriatic arthritis (PsA) is a destructive inflammatory arthritis that develops
in approximately 30% of patients with cutaneous psoriasis. Th17 cells
infiltrate psoriatic skin and joints and are central to the pathogenesis of
PsA. The aim of this study was to identify Th17 cell signaling genes that are
dysregulated in the affected joint of PsA patients and if these differences are
detected in peripheral blood.

Methods: Synovial
fluid cells from 8 PsA and 4 gout patients undergoing routine joint aspirations
were obtained and stored in TRIzol reagent. RNA was isolated by phenol-chloroform
extraction and purified with RNeasy miniprep kits. Peripheral blood from 24 PsA
and 19 controls was stored in Tempus tubes and total RNA was extracted
according to the manufacturer’s instructions. Quantitative RT-PCR arrays were used
to profile expression of 84 genes related to the Th17 regulatory network in synovial
and peripheral blood cells. Expression was quantified by the ΔΔCt
method and fold change differences were compared in synovial cells by logistic
regression and in peripheral blood by Student’s t test (p<0.05).

Results: Out
of 16 genes significantly dysregulated in PsA compared to gout synovial cells,
15 genes were up-regulated and one gene (STAT4) was down-regulated (Table 1). In
peripheral blood, 5 genes (IL-15, CXCL6, CLEC7A, CD3D and TLR4) were elevated
and 21 genes, including IL-8, IL-17C, CD4, STAT3, NFKB1 and TGFB1, were reduced
in PsA compared to controls. Five genes (CD4, CLEC7A, CXCL6, NFKB1 and IL8)
were significantly altered in both synovial and peripheral blood cells of PsA
patients compared to controls (gout or normal). Additionally, gene expression
was compared in paired synovial and peripheral blood cells in 4 PsA patients.
Eight genes were increased and 13 genes were reduced in PsA synovial cells
compared to peripheral blood cells (Table 2).

Conclusion: We
identified gene expression differences that may distinguish PsA from other
inflammatory arthritides such as gout. Five genes (CD4, CLEC7A, CXCL6, NFKB1
and IL8) were altered in both synovial fluid and peripheral blood, potentiating
their use as biomarkers of PsA. Differences between synovial and peripheral
blood cells contribute to our understanding of the biology of PsA and warrant
further investigation.

Table 1: Differences in
expression of Th17 signaling genes (p<0.05) in synovial cells obtained from
patients with PsA compared to that obtained from gout

Gene

Description

Fold Change

P-Value

FDR

IL6

Interleukin 6

10.68

0.009

0.139

CD4*

Cluster of differentiation 4

6.21

0.017

0.139

MMP9

Matrix metallopeptidase 9

5.44

0.021

0.139

CLEC7A*

C-type lectin domain family 7, member A

5.15

0.043

0.175

CCL1

Chemokine (C-C motif) ligand 1

5.13

0.010

0.139

CXCL6*

Chemokine (C-X-C motif) ligand 6

4.63

0.034

0.160

IL4

Interleukin 4

4.58

0.025

0.140

TIRAP

Toll-interleukin 1 receptor (TIR) domain containing adaptor protein

3.73

0.023

0.139

SOCS3

Suppressor of cytokine signaling 3

2.95

0.012

0.139

NFKB1*

Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

2.92

0.047

0.178

IL12RB1

Interleukin 12 receptor, beta 1

2.66

0.021

0.139

IL8*

Interleukin 8

2.54

0.019

0.139

TRAF6

TNF receptor-associated factor 6, E3 ubiquitin protein ligase

2.22

0.042

0.175

CD3E

CD3 antigen, epsilon polypeptide

1.84

0.017

0.139

SOCS1

Suppressor of cytokine signaling 1

1.75

0.030

0.151

STAT4

Signal transducer and activator of transcription 4

0.31

0.016

0.139

*Denotes genes that were dysregulated in synovial
and peripheral blood of PsA vs. controls (gout or normal)

Table 2: Expression of
Th17 signaling genes (p<0.05) in paired synovial and peripheral blood cells
of PsA patients

Gene

Description

Fold Change

P-Value

FDR

CCL1

Chemokine (C-C motif) ligand 1

1302.31

0.002

0.027

MMP13

Matrix metallopeptidase 13

413.92

0.007

0.045

CCL22

Chemokine (C-C motif) ligand 22

48.71

0.035

0.098

ICAM1

Intercellular Adhesion Molecule 1

33.24

0.008

0.045

CCL20

Chemokine (C-C motif) ligand 20

24.91

0.035

0.098

IL17RC

Interleukin 17 receptor C

3.84

0.029

0.097

STAT4

Signal transducer and activator of transcription 4

3.37

0.022

0.097

TRAF6

TNF receptor-associated factor 6, E3 ubiquitin protein ligase

2.06

0.027

0.097

GATA3

GATA binding protein 3

0.42

0.004

0.035

IL17D

Interleukin 17D

0.41

0.034

0.098

CD28

Cluster of differentiation 28

0.35

0.028

0.097

MMP9

Matrix metallopeptidase 9

0.29

0.004

0.035

SOCS3

Suppressor of cytokine signaling 3

0.28

0.042

0.102

TLR4

Toll-like receptor 4

0.28

0.041

0.102

CD3D

CD3d molecule, delta (CD3-TCR complex)

0.22

0.038

0.102

NFKB1

Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

0.22

0.003

0.035

TIRAP

Toll-interleukin 1 receptor (TIR) domain containing adaptor protein

0.12

0.005

0.035

IL27

Interleukin 27

0.095

0.010

0.050

MMP3

Matrix metallopeptidase 3

0.065

0.026

0.097

CSF2

Colony stimulating factor 2 (granulocyte-macrophage)

0.043

0.001

0.020

CXCL12

Chemokine (C-X-C motif) ligand 12

0.008

0.0004

0.020

 


Disclosure: F. Abji, None; R. Pollock, None; K. Liang, None; V. Chandran, None; D. Gladman, None.

To cite this abstract in AMA style:

Abji F, Pollock R, Liang K, Chandran V, Gladman D. A Comparison of Th17 Gene Expression in Psoriatic Arthritis Synovial Fluid and Peripheral Blood [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/a-comparison-of-th17-gene-expression-in-psoriatic-arthritis-synovial-fluid-and-peripheral-blood/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-comparison-of-th17-gene-expression-in-psoriatic-arthritis-synovial-fluid-and-peripheral-blood/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology